GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 154
- Registration Number
- NCT06532565
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 262
- Registration Number
- NCT06513312
- Locations
- 🇫🇷
APHP Bichat Claude-Bernard Hospital, Paris, France
🇬🇧Caldecot Centre, Kings College Hospital, Kings College Hospital NHS Foundation Trust, London, United Kingdom
🇫🇷Hopital Saint Louis - Assistance Publique des Hopitaux de Paris, Paris, France
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 520
- Registration Number
- NCT06486441
- Locations
- 🇯🇵
Mie University Hospital, Mie, Japan
🇯🇵Hyogo Cancer Center, Hyogo, Japan
🇺🇸City of Hope, Irvine, California, United States
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
- Conditions
- Interventions
- Drug: E/C/F/TAFDrug: F/TAF (High Dose Tablet)Drug: B/F/TAF (Low Dose)Drug: E/C/F/TAF (Low Dose)Drug: F/TAF (Low Dose Tablet)Drug: F/TAF (Lowest Dose Tablet)Drug: F/TAF (High Dose TOS)Drug: B/F/TAF (High Dose)Drug: F/TAF (Low Dose TOS)Drug: B/F/TAF (Lowest Dose TOS)Drug: F/TAF (Lowest Dose TOS)Drug: B/F/TAF (High Dose TOS)Drug: Cobicistat (High Dose)Drug: 3rd ARV AgentDrug: Cobicistat (Low Dose)Drug: Cobicistat (TOS)Drug: B/F/TAF (Low Dose TOS)Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)Drug: ATVDrug: DRVDrug: Lopinavir Boosted with ritonavir (LPV/r)
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 350
- Registration Number
- NCT06337032
- Locations
- 🇦🇷
Helios Salud, Buenos Aires, Argentina
🇿🇦Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa
🇿🇦Be Part Yoluntu Centre, Paarl, South Africa
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 546
- Registration Number
- NCT06333808
- Locations
- 🇦🇷
Fundacion Huesped, Buenos Aires, Argentina
🇨🇦Regina General Hospital, Regina, Canada
🇩🇪Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 228
- Registration Number
- NCT06290934
- Locations
- 🇺🇸
US San Diego Health System, La Jolla, California, United States
🇺🇸Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
🇺🇸University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center(Drug shipment)-Research Pharmacy, Miami, Florida, United States
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 254
- Registration Number
- NCT06167317
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇱Chaim Sheba Medical Center, Tel Hashomer, Israel
Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT06104306
- Locations
- 🇺🇸
Franco Felizarta, MD, Bakersfield, California, United States
🇺🇸BIOS Clinical Research, Palm Springs, California, United States
🇺🇸UC San Diego AntiViral Research Center (AVRC), San Diego, California, United States
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 250
- Registration Number
- NCT06101329
- Locations
- 🇺🇸
Cornell Clinical Trials Unit, New York Presbyterian Hospital - Weill Cornell Medicine, New York, New York, United States
🇺🇸UAB, 1917 Research Clinic, Birmingham, Alabama, United States
🇺🇸UCSD Antiviral Research Center (AVRC), San Diego, California, United States
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 180
- Registration Number
- NCT06101342
- Locations
- 🇺🇸
ICAP at Columbia University- Bronx Prevention Center, Bronx, New York, United States
🇺🇸University of Pennsylvania, Division of Infectious Diseases Penn Prevention Research Unit, Philadelphia, Pennsylvania, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States